Kazia Therapeutics (ASX:KZA) Announces Summary Of New Paxalisib Data Presented At SNO Annual Meet

  • November 18, 2020 04:56 PM AEDT
  • Team Kalkine
    Team Kalkine
    Team Kalkine
    16991 Posts

    Team Kalkine comprises of experts who understand various markets nuances and are enthusiastic and passionate to provide best possible offerings in the form of insights and stories. The team has rich experience of working across different markets with...

Australia based biotech company focused on oncology, Kazia Threapeutics Limited (ASX:KZA), on 18 November 2020, in an ASX announcement, shared a summary of new paxalisib data submitted at the annual meeting of Society for Neuro-Oncology (SNO), to be held virtually from 19-21 November 2020.

Key pointers feature:

  • The latest interim study of paxalisib phase 2 study in glioblastoma is very much consistent with the previous data.
  • The analysis suggested median progression-free survival of 8.4 months.
  • Median overall survival of 17.5 months reported.
  • First significant presentation of safety data at a 60mg dose showcases profile similar to the previous experience. Most common toxicities include rash, stomatitis and hyperglycemia.

Kazia CEO Dr James Garner shared that this is quite reassuring data from the glioblastoma study. This confirms that the earlier results with the data are now much more mature.

Meanwhile, the KZA stock soared up by 34.453% at $1.600 with a market capitalisation of $150.13 million at 2:14 PM AEDT.

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK